by Michael Erman
London: Pfizer’s 15-day course of COVID-19 antiviral treatments The following symptoms were not relieved with Paxlovid Long Covidaccording to a study Stanford University Researchers.
Currently, there is no proven treatment specifically for long Covid, in which many symptoms can persist for several months after the initial symptom. coronavirus infection,
Scientists and patients were hopeful that Pfizer’s two-drug oral treatment would relieve symptoms of long-haul COVID after patients reported that Paxlovid helped them.
But the 15-week, 155-participant study did not show that the 15-day course was more effective than a placebo in reducing fatigue, brain fog, shortness of breath, body aches, or gastrointestinal or cardiac symptoms. On average, trial participants were sicker than they were 16 months before joining the trial.
“We did not see any measurable difference in patient-reported outcomes across the six overall symptoms,” Dr. Upinder Singh, a professor at Stanford Medicine, said in an interview. “We also did not see any benefit across individual symptoms.”
Dr Singh said he believed there was still a need for further studies into the treatment of long-haul Covid, possibly over a course longer than 15 days or in patients who have not been chronically ill.
He said the study showed that Paxovid, which is currently prescribed as a 5-day course after infection or symptom onset, is safe when used for up to 15 days.
Pfizer said in a statement that these results will not have any impact on its other planned programs. Collaborative Studies Paxlovid is being touted as a potential treatment for long Covid.
Paxovid is the most commonly prescribed home remedy for COVID-19 in the U.S. It is approved to treat COVID in adults who are at risk. Serious complications From illness.
In Pfizer’s original clinical trialPaxovid was shown to reduce hospitalization and death from Covid by about 90% for unvaccinated people at risk of severe disease. In another trial, Pfizer was unable to show a benefit for people at standard risk, including Vaccinated Patients,
Pfizer funded the long-haul Covid trial. In addition to the Stanford researchers, scientists from Kaiser Permanente North California and Pfizer also contributed to the study. (Reporting by Michael Erman; Editing by Bill Berkrot)
pfizers-paxlovid-fails-as-15-day-treatment-for-long-covid-study-finds-et-healthworld-pharma
